Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 5/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.31 |
| ▸ | WDR5 | P61964 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27025831 | 0.93 | SOS1 (0.38) | CDK9SOS1GRM5GRM1TLR7 | |
| SCHEMBL27007926 | 0.91 | SOS1 (0.38) | CDK9SOS1GRM5GRM1TLR7 | |
| SCHEMBL30745991 | 0.90 | SOS1 (0.37) | CDK9SOS1GRM5GRM1TLR7 | |
| SCHEMBL27007644 | 0.90 | SOS1 (0.37) | CDK9SOS1GRM5GRM1TLR7 | |
| SCHEMBL27007695 | 0.88 | CDK9 (0.36) | CDK9SOS1GRM5GRM1TLR7 | |
| SCHEMBL27025875 | 0.87 | CDK9 (0.37) | CDK9SOS1GRM5GRM1TLR7 | |
| SCHEMBL27025909 | 0.87 | NAMPT (0.36) | SOS1GRM5GRM1NAMPT | |
| SCHEMBL27025972 | 0.84 | TLR7 (0.38) | CDK9SOS1GRM5GRM1TLR7 | |
| SCHEMBL27025886 | 0.84 | NAMPT (0.39) | CDK9SOS1GRM5GRM1NAMPT | |
| SCHEMBL27025881 | 0.83 | CDK9 (0.37) | CDK9GRM5GRM1NAMPTWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMCIAL DIVERSITY CENTER, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018121-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | ERG28, CYP51A1, MANBA | CDK9 872/4885SOS1 4010/4885GRM5 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.